XML 37 R30.htm IDEA: XBRL DOCUMENT v3.25.2
Segment (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Summary of Reconciles Reported Revenues to Net (Loss) Income under Significant Expense Principle The following table

reconciles reported revenues to net (loss) income under the significant expense principle for the three and six months ended June 30, 2025 and 2024 (in thousands):

 

 

For the Three Months
Ended June 30,

 

 

For the Six Months
Ended June 30,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

 

 

Research and Development Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

RAP-219 program external expenses

 

$

9,685

 

 

$

4,846

 

 

$

17,648

 

 

$

8,747

 

Preclinical programs external expenses

 

 

4,722

 

 

 

5,648

 

 

 

7,968

 

 

 

9,582

 

R&D personnel-related costs (including stock-based
   compensation)

 

 

6,666

 

 

 

4,590

 

 

 

13,452

 

 

 

8,607

 

 Other costs

 

 

1,607

 

 

 

605

 

 

 

3,184

 

 

 

1,257

 

General and Administrative Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

G&A personnel-related costs (including stock-based
   compensation)

 

 

5,045

 

 

 

3,436

 

 

 

10,004

 

 

 

5,833

 

Professional and consulting costs

 

 

920

 

 

 

1,108

 

 

 

2,584

 

 

 

2,973

 

Facility related and other

 

 

851

 

 

 

567

 

 

 

1,764

 

 

 

895

 

Loss from operations

 

$

(29,496

)

 

$

(20,800

)

 

$

(56,604

)

 

$

(37,894

)

Interest income

 

 

2,764

 

 

 

2,679

 

 

 

5,809

 

 

 

4,494

 

Change in fair value of preferred stock tranche right liability

 

 

 

 

 

 

 

 

 

 

 

(7,390

)

Net loss

 

$

(26,732

)

 

$

(18,121

)

 

$

(50,795

)

 

$

(40,790

)